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The most frequently occurring treatment-related, treat-
ment-emergent adverse events were decreased appetite 
(22 %), dry skin (22 %), nausea (22 %) and vomiting 
(22 %). In PK analyses, individual exposures observed 
with 600 mg tablet-E were within the range of data at 
steady state from previous studies of 400 mg tablet-A and 
600 mg capsule-A. Five patients (28 %) had stable disease 
as best response.
Conclusions With pilaralisib tablet-E, the RP2D was 
600 mg QD, drug exposure was similar to the 400 mg tab-
let-A and 600 mg capsule-A formulations, and safety was 
consistent with the known safety profile of pilaralisib.
Keywords PI3K · Pilaralisib · Tablets · Pharmacokinetics · 
Solid tumors · Lymphoma
Introduction
The phosphoinositide 3-kinase (PI3K)/mammalian target 
of rapamycin (mTOR) pathway is essential for numerous 
processes in normal cells, including growth and metabo-
lism [1–3], and its dysregulation is involved in the patho-
genesis of many tumor types [3–5]. Molecular alterations in 
the PI3K/mTOR pathway occur frequently in solid tumors 
and lymphomas [3–10], and activation of the PI3K/mTOR 
pathway is associated with poor survival [9, 11]. Several 
PI3K inhibitors in clinical development have shown antitu-
mor activity in multiple tumor types [12–22].
Pilaralisib (SAR245408; XL147) is an oral, selective, 
pan-class I PI3K inhibitor [23, 24]. Pilaralisib inhibits the 
PI3K α, β, γ and δ isoforms with half-maximal inhibitory 
concentration (IC50) values of 48, 617, 10 and 260 nmol/L, 
respectively [23, 24]. Pilaralisib has been investigated in 
Phase I/II trials in several advanced solid tumors, including 
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endometrial carcinoma and breast cancer, and also in lym-
phoma and chronic lymphocytic leukemia (CLL) [23, 25–
28]. In a Phase I trial, pilaralisib demonstrated preliminary 
antitumor activity in patients with advanced solid tumors and 
was associated with decreased PI3K pathway signaling in 
tumor tissue [23], and in an expansion cohort of 25 patients 
with lymphoma or CLL, five patients (50 %) with CLL and 
three patients (20 %) with lymphoma had a partial response 
[26]. Two pilaralisib formulations were examined in Phase 
I/II trials: a powder-in-capsule formulation (capsule-A), in 
which the free base of the polymorph A active pharmaceu-
tical ingredient is contained in size 0 hard gelatin capsules; 
and an immediate-release tablet formulation (tablet-A) con-
taining 50 % (w/w) of free-base polymorph A. The maxi-
mum tolerated dose (MTD) and recommended Phase II dose 
(RP2D) of pilaralisib polymorph A in capsule formulation 
(capsule-A) were established as 600 mg once daily (QD) 
[23]. The MTD of pilaralisib in tablet formulation has not 
been established; however, in a Phase I trial of tablet-A, the 
RP2D was determined as 400 mg QD (Sanofi, data on file).
During development, a new polymorphic form of pila-
ralisib was identified: polymorph E, which is more thermo-
dynamically stable than the polymorph A form examined 
previously. Both forms of pilaralisib (polymorph A and E) 
were characterized by differential scanning calorimetry. 
Polymorph E has a melting point and a melting enthalpy 
higher than those of polymorph A, and polymorph E is 
always more stable compared with polymorph A at ambient 
pressure (monotropic relation between both polymorphs). 
Therefore, an immediate-release, film-coated tablet for-
mulation of pilaralisib polymorph E (tablet-E), containing 
50 % (w/w) active pharmaceutical ingredient, was devel-
oped for use in further studies. This Phase I study was 
conducted to assess the safety, tolerability and plasma PK 
of pilaralisib as a tablet formulation of polymorph E in 
patients with solid tumors or lymphoma.
Methods
Patient population
Eligible patients were aged ≥18 years and had either a his-
tologically confirmed solid tumor that was metastatic or 
unresectable, or relapsed or refractory lymphoma. Stand-
ard therapies were either contraindicated, not tolerated or 
no longer effective, and no therapeutic alternative existed 
or no therapy was known to prolong survival. Patients 
were required to have an Eastern Cooperative Oncol-
ogy Group (ECOG) performance status ≤1 and adequate 
organ and marrow function, including absolute neutro-
phil count ≥1.5 × 109/L (solid tumors) or ≥1.0 × 109/L 
(lymphoma); platelets ≥100 × 109/L (solid tumors) or 
≥30 × 109/L (lymphoma); hemoglobin ≥90 g/L (solid 
tumors) or ≥80 g/L (lymphoma); and fasting plasma glu-
cose <8.9 mmol/L.
Study design
This was a Phase I, open-label, dose-escalation study with 
a cohort expansion phase in patients with solid tumors or 
lymphoma (NCT01943838). Pilaralisib capsule-A and 
pilaralisib tablet-A were given without food in the previ-
ous Phase I and II clinical studies (patients fasted for 2 h 
before and 1 h after drug intake). In the current study, 
patients received pilaralisib polymorph E tablets, given QD 
with the morning meal approximately at the same time of 
the day, for two 28-day treatment cycles. This dosing was 
chosen because it was the most convenient to patients. 
On Cycle 1 Day 1 and Cycle 2 Day 1 only, a standardized 
moderate-fat breakfast was given to patients 30 min prior to 
pilaralisib administration, and patients fasted for 4 h after 
pilaralisib administration. After Cycle 2, eligible patients 
were allowed to continue treatment in an extension study 
(NCT01587040); the purpose of the extension study was 
to determine the long-term safety and tolerability of pila-
ralisib as a monotherapy or as part of a combination regi-
men in patients who were benefiting from treatment. All 
other patients were followed up for safety for a minimum 
of 30 days (±3 days) after last study drug administration. 
The primary objective was to assess the safety and plasma 
pharmacokinetics (PK) of pilaralisib polymorph E tablets 
administered QD in patients with solid tumors or lym-
phoma. Exploratory objectives were to assess the pharma-
codynamic effects of pilaralisib and the antitumor activity 
of pilaralisib by RECIST 1.1. This study was conducted 
in compliance with the recommendations of the Hel-
sinki Declaration, and all relevant international guidelines 
and national laws and regulations. Informed consent was 
obtained from all patients.
Dose escalation and dose‑limiting toxicities
A modified ‘3 + 3’ dose-escalation design was employed. 
It was not intended to reach a formal MTD and dose esca-
late until high toxicity. Information collected during Cycle 
1 was used to determine dose-limiting toxicities (DLTs). 
The DLT-evaluable population consisted of all patients 
who had complete assessments for DLT evaluation and 
received ≥75 % of doses of study treatment during Cycle 
1, or received partial doses of study treatment but devel-
oped DLTs during Cycle 1. A DLT was defined as any 
of the following treatment-related, treatment-emergent 
adverse events (TEAEs) occurring during Cycle 1: Grade 
≥3 nausea, vomiting or diarrhea lasting >2 days despite 
optimal prophylaxis and/or treatment; any other Grade ≥3 
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non-hematologic toxicity except asthenia lasting <10 days; 
any Grade 4 non-hematologic toxicity; any toxicity result-
ing in a treatment interruption lasting >2 weeks; Grade 4 
neutropenia lasting ≥4 days; febrile neutropenia, defined 
as Grade ≥3 neutropenia associated with a single tempera-
ture >38.3 °C or a temperature ≥38 °C sustained for >1 h; 
neutropenic infection; Grade 4 thrombocytopenia; Grade 4 
anemia; any TEAE that, in the opinion of the investigator, 
was of potential clinical significance such that further dose 
escalation would expose patients to unacceptable risk; ina-
bility to take 75 % or more of the planned numbers of study 
doses in Cycle 1 due to a TEAE; or interruption of study 
drug for more than 14 days due to a TEAE that began dur-
ing Cycle 1. Dose escalation was discontinued if ≥2 out of 
6 DLT-evaluable patients experienced a DLT. In the event 
of discontinuation of dose escalation, up to 12 additional 
patients were enrolled to further assess safety and PK at the 
selected dose level and confirm it as the RP2D of tablet-E.
Safety assessments
Safety evaluation included assessment of: TEAEs, serious 
AEs (SAEs) and DLTs graded with National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
(NCI-CTCAE) version 4.03; laboratory parameters; vital 
signs; ECOG performance status; and electrocardiogram 
parameters.
Pharmacokinetic assessments
Plasma concentrations of pilaralisib were measured pre-
dose on Days 1, 2, 8 and 15 of Cycle 1 and Days 1 and 2 
of Cycle 2 and at 1, 2, 3, 4, 6, 8 and 10 h after dosing on 
Cycle 1 Day 1 and Cycle 2 Day 1 using a validated liquid 
chromatography method coupled with tandem mass spec-
trometry (LC–MS/MS), which had a lower limit of quan-
tification of 1.00 ng/mL. Non-compartmental analysis was 
conducted with validated software (Pharmacokinetic Data 
Management services [PKDMS] version 3.1 with Win-
NonLin Professional, version 5.2.1, Pharsight [Princeton, 
USA]). PK parameters, including maximum concentration 
(Cmax), time to Cmax (tmax) and area under the concentra-
tion–time curve from time 0 to 24 h (AUC0–24) and from 
time zero to tlast (AUClast), were assessed on Cycle 1 Day 1 
and on Cycle 2 Day 1. In addition, Ctrough evaluations were 
obtained on Days 2, 8 and 15 of Cycle 1 and Days 1 and 2 
of Cycle 2.
Pharmacodynamic assessments
Inhibition of pAKT level in platelets was used to document 
the pharmacodynamic impact of pilaralisib on PI3K signal-
ing [29]. Blood samples for pharmacodynamic analysis of 
pilaralisib were collected pre-dose on Cycle 1 Days 1, 2, 8 
and 15 and Cycle 2 Days 1 and 2 and post-dose at 2 and 4 h 
on Cycle 1 Day 1 and 2, 4, 8 and 10 h on Cycle 2 Day 1.
Blood samples were kept at room temperature for less 
than 30 min and placed in a swing-bucket rotor with brake 
off for 20 min at 20 °C, at 190–230 g. The upper phase 
(platelet-rich plasma) was collected without disturbing the 
cell layer. Platelets were then pelleted by centrifugation of 
platelet-rich plasma in a swing-bucket rotor with brake on, 
at 980 g for 20 min, at 20 °C. The supernatant and the pel-
let were separated, and the pellet was frozen in dry ice and 
stored at −70 °C or below. Each platelet pellet was lysed in 
200 μL of cell extraction buffer on ice for 30 min and then 
centrifuged for 15 min at 15,000g at +4 °C. Supernatant 
was transferred to a new tube, and samples were assayed 
immediately. Platelet samples were analyzed using the 
Mesoscale Discovery Multispot duplex sandwich immu-
noassay for p(S473)AKT and T-AKT. Each platelet extract 
sample was loaded on the pre-coated plate with capture 
antibodies against p(S473)AKT and T-AKT at 100 μg per 
well, and a range of SNU-5 lysates were used as quality 
controls. The SNU-5 range was from 3.125 to 100 μg per 
well. Analyses were performed in triplicate. After an over-
night incubation on a platform shaker at +4 °C, plates 
were washed three times and 25 μL of the second antibody 
was added. After a second incubation of 1 h on a platform 
shaker at room temperature and a second step of washing, 
150 μL of the read buffer was added. Plates were read at 
562 nm in a SECTOR Imager (Rockville, USA). Back-
ground was corrected by subtracting the average measure-
ment of the blank standard replicates from the measure-
ments of all individual platelet lysate replicates. Data were 
calculated in AU/μg proteins by dividing raw data by the 
amount of protein loaded. Each p(S473)AKT sample was 
normalized against T-AKT by dividing the p(S473)AKT 
data by the T-AKT data.
Efficacy assessments
Tumors were examined using computed tomography (CT) 
or positron emission tomography–CT imaging performed 
at baseline and at end-of-treatment visit. Responses were 
assessed by the investigator according to RECIST 1.1. 
Patients showing disease progression at the end-of-treatment 
visit were not eligible for the treatment extension study.
Results
Patient population
Eighteen patients were enrolled and received pilaralisib 
(six patients at 400 mg QD and 12 patients at 600 mg QD). 
 Cancer Chemother Pharmacol
1 3
Median age was 58.5 years (range 27–83), and all patients 
had an ECOG performance status of 0 or 1 at baseline 
(Table 1). Fourteen patients (78 %) had a metastatic solid 
tumor, of which only adrenal gland adenocarcinoma was 
reported in more than one patient (n = 2). Four patients 
(22 %) had lymphoma, including two patients (11 %) with 
mantle cell lymphoma. Seventeen patients (94 %) had 
received prior chemotherapy, and the median number of 
prior systemic regimens was 3.0 (range 1–7).
Median duration of treatment was 7.9 weeks (range 
3–8). Sixteen patients (89 %) received two cycles of pilaral-
isib and two patients (11 %) received one cycle. The mean 
relative dose intensity of pilaralisib was 85 % in the overall 
safety population, 92 % in the 400 mg QD dose cohort and 
82 % in the 600 mg QD dose cohort. Four patients discon-
tinued study treatment due to disease progression or AEs. 
Five patients (28 %) received further pilaralisib treatment 
in a treatment extension study.
Dose escalation and dose‑limiting toxicities
Six patients were treated at the 400 mg QD dose level with 
no DLT reported. Of the first three patients treated at the 
600 mg QD dose level, one patient had a DLT (Grade 3 
rash maculopapular). Three additional patients were treated 
with 600 mg QD, with no DLT reported. To further inves-
tigate the RP2D, six additional patients were enrolled and 
treated with 600 mg QD, of which one patient experienced 
two DLTs (Grade 4 lipase increased and Grade 3 rash gen-
eralized). Thus, two of 12 patients (17 %) treated with pila-
ralisib 600 mg QD had DLTs, which is a DLT rate of <1/3 
patients. At this point, the study committee made a joint 
decision that no further dose escalation was to be carried 
out, because the study was not designed to dose escalate to 
the MTD.
Safety
All of the 18 patients treated experienced at least one 
TEAE regardless of relationship to pilaralisib. The most 
frequently reported TEAEs regardless of causality were 
constipation (33 %), fatigue (28 %), nausea (28 %), 
vomiting (28 %), decreased appetite (22 %) and dry 
skin (22 %) (Table 2). Grade ≥3 TEAEs were reported 
in nine patients (50 %); no individual Grade ≥3 TEAE 
occurred in more than one patient. TEAEs related to pila-
ralisib were reported in 17 patients. The most frequently 
reported treatment-related TEAEs were decreased appe-
tite (22 %), dry skin (22 %), nausea (22 %), vomiting 
(22 %) and fatigue (17 %) (Table 2). Grade ≥3 treatment-
related TEAEs were reported in five patients (28 %) and 
included decreased appetite, vomiting, blood alkaline 
phosphatase (ALP) increased, lipase increased, photosen-
sitivity reaction, rash maculopapular, rash generalized and 
hypertension.
Six patients (33 %) had a skin-related TEAE, including 
rash maculopapular (11 %), dermatitis acneiform (11 %), 
rash pruritic (6 %) and rash generalized (6 %). Grade ≥3 
skin-related TEAEs reported were Grade 3 rash maculo-
papular and Grade 3 rash generalized, each affecting one 
patient in the 600 mg QD dose cohort. Hepatic-related 
TEAEs were reported in three patients (17 %), which 
Table 1  Patient disease characteristics and treatment history
ECOG PS Eastern Cooperative Oncology Group performance status, QD once daily
Pilaralisib 400 mg QD (n = 6) Pilaralisib 600 mg QD (n = 12) All patients (N = 18)
Median age, years (range) 60 (27–73) 58 (45–83) 58.5 (27–83)
Male, n (%) 5 (83.3) 6 (50.0) 11 (61.1)
Disease, n (%)
 Solid tumor 5 (83.3) 9 (75.0) 14 (77.8)
 Lymphoma 1 (16.7) 3 (25.0) 4 (22.2)
ECOG PS, n (%)
 0 3 (50.0) 1 (8.3) 4 (22.2)
 1 3 (50.0) 11 (91.7) 14 (77.8)
 2 0 0 0
Median number of prior regimens (range) 5.0 (2–7) 2.0 (1–7) 3.0 (1–7)
Most common prior systemic anticancer therapies, n (%)
 Cisplatin 3 (50.0) 5 (41.7) 8 (44.4)
 Cyclophosphamide 3 (50.0) 3 (25.0) 6 (33.3)
 Doxorubicin hydrochloride 3 (50.0) 3 (25.0) 6 (33.3)
 Fluorouracil 2 (33.3) 3 (25.0) 5 (27.8)
 Vincristine 2 (33.3) 3 (25.0) 5 (27.8)
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reached Grade ≥3 in one patient in the 400 mg cohort 
(ALP increased and gamma-glutamyltransferase [GGT] 
increased).
The most frequently occurring on-treatment biochem-
istry abnormalities were hyperglycemia (72 %), ALP 
increased (50 %), hyponatremia (39 %) and hypocalcemia 
(33 %). Grade ≥3 biochemistry abnormalities included 
ALP increased, hyponatremia, hypophosphatemia and 
lipase increased, occurring in one patient each (6 %). The 
most frequently occurring hematologic abnormalities were 
anemia (94 %), lymphopenia (67 %), leukopenia (33 %) 
and thrombocytopenia (28 %). Grade ≥3 on-treatment 
hematologic abnormalities were reported only in the pila-
ralisib 600 mg QD cohort and included lymphopenia (five 
patients, 28 %), anemia (two patients, 11 %) and thrombo-
cytopenia (one patient, 6 %).
Eight patients (44 %) experienced at least one SAE. 
Treatment-related SAEs occurred in one patient in the 
400 mg QD dose cohort (Grade 3 vomiting) and one patient 
in the 600 mg QD dose cohort (Grade 4 lipase increased, 
which led to treatment discontinuation). One patient in the 
600 mg QD dose cohort had a dose reduction due to Grade 
3 maculopapular rash. Five patients (28 %) had TEAEs 
leading to dose delays, including GGT increased, abdomi-
nal infection, skin infection, rash generalized and rash mac-
ulopapular. One patient in the 600 mg QD dose cohort died 
as a result of Grade 5 sepsis secondary to an SAE of Grade 
3 skin infection (both were considered unrelated to pilaral-
isib treatment).
Pharmacokinetics
Pilaralisib PK parameters are summarized in Table 3. 
At both dose levels, pilaralisib showed an increase in 
plasma exposure at Cycle 2 Day 1 compared with Cycle 
1 Day 1, indicating accumulation with repeated dos-
ing (AUC0–24 increased by 6.21-fold and 2.98-fold for 
the 400 and 600 mg doses, respectively). Pilaralisib was 
absorbed slowly in both dose groups (tmax ranged from 4.98 
to 6.99 h). A 1.5-fold increase in pilaralisib dose (400–
600 mg) resulted in a twofold increase in plasma exposure 
(Cmax and AUC0–24) following a single dose (Cycle 1, Day 
1), but exposure was comparable for both dose levels fol-
lowing repeated dosing (Cycle 2, Day 1; Fig. 1), suggest-
ing potential saturable absorption. Pilaralisib exposure 
showed high inter-patient variability, with percentage coef-
ficients of variation (% CV) for Cmax and AUC0–24 of up 
to 66 and 58 %, respectively. Pilaralisib appeared to reach 
steady-state levels after 15 days of daily dosing in Cycle 
1 and remained at steady state during Cycle 2. The range 
of exposures (Cmax and AUC0–24) seen after repeated doses 
of 600 mg tablet-E was consistent with previous studies 
of both 400 mg tablet-A (Sanofi data on file) and 600 mg 
capsule-A [23].
Efficacy
Three of six patients in the 400 mg QD dose cohort and 
two of 12 patients in the 600 mg QD dose cohort had stable 
Table 2  Most frequently 
occurring treatment-emergent 
adverse events (>15 % of 
patients)
TEAE treatment-emergent adverse event, QD once daily
TEAEs, n (%) Pilaralisib 400 mg QD 
(n = 6)
Pilaralisib 600 mg QD 
(n = 12)
Total (N = 18)
All grades Grade ≥3 All grades Grade ≥3 All grades Grade ≥3
TEAEs regardless of causality
 Constipation 3 (50.0) 1 (16.7) 3 (25.0) 0 6 (33.3) 1 (5.6)
 Fatigue 2 (33.3) 0 3 (25.0) 0 5 (27.8) 0
 Nausea 2 (33.3) 0 3 (25.0) 0 5 (27.8) 0
 Vomiting 2 (33.3) 1 (16.7) 3 (25.0) 0 5 (27.8) 1 (5.6)
 Decreased appetite 2 (33.3) 1 (16.7) 2 (16.7) 0 4 (22.2) 1 (5.6)
 Dry skin 2 (33.3) 0 2 (16.7) 0 4 (22.2) 0
 Dermatitis acneiform 1 (16.7) 0 2 (16.7) 0 3 (16.7) 0
 Diarrhea 0 0 3 (25.0) 0 3 (16.7) 0
 Pyrexia 0 0 3 (25.0) 0 3 (16.7) 0
 Tumor pain 1 (16.7) 0 2 (16.7) 1 (8.3) 3 (16.7) 1 (5.6)
Treatment-related TEAEs
 Decreased appetite 2 (33.3) 1 (16.7) 2 (16.7) 0 4 (22.2) 1 (5.6)
 Dry skin 2 (33.3) 0 2 (16.7) 0 4 (22.2) 0
 Nausea 1 (16.7) 0 3 (25.0) 0 4 (22.2) 0
 Vomiting 1 (16.7) 1 (16.7) 3 (25.0) 0 4 (22.2) 1 (5.6)
 Fatigue 1 (16.7) 0 2 (16.7) 0 3 (16.7) 0
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disease as best response (28 % of patients overall). Among 
four patients with lymphoma, two had stable disease after 
two cycles of pilaralisib (one patient in the 400 mg QD 
cohort and one patient in the 600 mg QD cohort). No objec-
tive responses according to RECIST 1.1 were observed. All 
patients with stable disease were enrolled into the treatment 
extension study.
Pharmacodynamics
The pharmacodynamic impact of pilaralisib on the PI3K 
pathway was assessed by examining modulation of pAKT 
level in platelet samples. Platelet pAKT data were collected 
from all patients enrolled. In the 400 mg QD cohort (n = 6), 
pilaralisib exposure was observed in all six patients, with a 
plateau reaching 100,000 ng/mL (184 µM) in three patients. 
Among these three patients, only one had a sustained (≥8 h) 
pharmacodynamic effect (75–80 % inhibition) correlating 
with drug exposure >150,000 ng/mL (277 µM). One patient 
had moderate pAKT impact (~65 % inhibition) with drug 
exposure >100,000 ng/mL (184 µM). In the 600 mg QD 
cohort (n = 12), pilaralisib exposure above 100,000 ng/mL 
(184 µM) was observed in eight patients. Of these, three 
patients had a substantial impact (>75 % inhibition), cor-
relating with drug exposure. No pharmacodynamic impact 
was observed in the remaining five patients.
Discussion
Pilaralisib has been investigated as tablet and capsule for-
mulations of polymorph A in Phase I/II trials in solid tumors 
and lymphoma [23, 25–28]. This Phase I dose-escalation 
study evaluated the RP2D of pilaralisib as a tablet formula-
tion of a more thermodynamically stable form, polymorph E 
(tablet-E), in patients with solid tumors or lymphoma. The 
safety profile of pilaralisib tablet-E 600 mg QD in this study 
was consistent with the known safety profile of pilaralisib 
capsule-A and tablet-A [23, 25–28] and with that of other 
PI3K inhibitors in solid tumors and lymphoma [17–22], with 
gastrointestinal and skin toxicities among the most com-
monly occurring TEAEs. The incidence of TEAEs was simi-
lar between the 400 mg QD and 600 mg QD dose cohorts.
Table 3  Plasma pilaralisib pharmacokinetic parameters on Cycle 
1 Day 1 and Cycle 2 Day 1 (mean ± standard deviation (geometric 
mean) [% coefficient of variation])
a  Median (range); b tlast for AUClast estimation was 10 h for all 
patients; c one patient had only one PK measurement during Day 1 of 
Cycle 2; the concentration was considered as Cmax and time as tmax by 
default; d n = 5; e n = 9
AUC area under the curve, Cmax maximum concentration, tmax time to 
maximum concentration, QD once daily
PK parameter Pilaralisib 400 mg QD Pilaralisib 600 mg QD
Cycle 1 Day 1
 n 6 12
 Cmax, ng/mL 24,200 ± 13,600 50,100 ± 19,900
(19,500) [56.0] (43,000) [39.8]
 tamax, h 6.99 (2.08–9.85) 4.98 (2.00–9.92)
 AUCblast, ng h/mL 168,000 ± 104,000 333,000 ± 134,000
(132,000) [61.6] (286,000) [40.3]
 AUC0–24, ng h/mL 441,000 ± 242,000 909,000 ± 349,000
(360,000) [55.0] (790,000) [38.4]
Cycle 2 Day 1
 n 6 11
 Cmax, ng/mL 106,000 ± 69,900 140,000 ± 48,800
(83,800) [65.7]c (131,000) [34.9]c
 tamax, h 6.79 (4.00–24.5)
c 6.00 (1.00–24.3)c
 AUCblast, ng h/mL 1,040,000 ± 567,000 1,100,000 ± 459,000
(925,000) [54.3]d (1,010,000) [41.7]
 AUC0–24, ng h/mL 2,740,000 ± 1,580,000 2,710,000 ± 1,160,000
(2,380,000) [57.8]d (2,450,000) [42.9]e
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Fig. 1  Mean (± SD) plasma pilaralisib concentration–time profiles 
following a single (Day 1, Cycle 1) and b repeated (Day 1, Cycle 2) 
oral dose
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Efficacy was limited in this small, heavily pre-treated 
patient population: no objective responses were observed 
at the end-of-treatment period (two cycles) and 28 % of 
patients had stable disease. This limited efficacy was con-
sistent with previous trials of pilaralisib in solid tumors 
[23, 25–28]. In a Phase I trial of pilaralisib in 69 patients 
with advanced solid tumors, only one patient had a par-
tial response (overall response rate [ORR] 1 %) [23]. In 
a Phase II trial of pilaralisib in 67 patients with advanced 
endometrial cancer, the ORR was 6 % [28]. Limited anti-
tumor activity has also been seen in trials of other PI3K 
inhibitors in patients with solid tumors [18–20, 30–34]. It is 
unlikely that therapeutic effects of PI3K inhibitors in solid 
tumors can be demonstrated by objective shrinkage of tar-
get lesions; instead, this class of molecules most likely has 
cytostatic effects of inducing tumor stabilization and poten-
tially prolonging progression-free survival. A true assess-
ment of the efficacy of these compounds would require ran-
domized trials.
PK analyses indicated that pilaralisib reached steady-
state levels after 15 days of daily dosing in Cycle 1. 
Steady-state exposure with pilaralisib 600 mg tablet-E 
dosing was within the expected range from previous tri-
als of pilaralisib with 400 mg tablet-A (Sanofi data on 
file) and 600 mg capsule-A dosing [23]. Based on both 
PK and safety, and the likelihood of achieving greater 
clinical activity with the higher dose, there is clinical 
rationale to further investigate pilaralisib 600 mg tablet-E 
as RP2D.
Inhibition of pAKT level in platelets was used to docu-
ment the pharmacodynamic impact of pilaralisib on PI3K 
signaling. Modulation of the PI3K pathway (pAKT level) 
was observed when the pilaralisib concentration reached at 
least 184 µM in two out of six patients in the 400 mg QD 
cohort and in three out of eight patients in the 600 mg QD 
cohort. Pharmacodynamic impact observed was consistent 
with results from the previous Phase I study of pilaralisib in 
solid tumors [23].
In summary, this Phase I dose-escalation study dem-
onstrated that the more thermodynamically stable tablet 
formulation of pilaralisib polymorph E (tablet-E) 600 mg 
QD had a similar safety profile and similar plasma expo-
sure compared with previous trials with pilaralisib 400 mg 
tablet-A QD and 600 mg capsule-A QD. Pilaralisib tab-
let-E 600 mg QD was the recommended dose for further 
development.
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